Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
| Cat. No. | Species | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|
| TL3-R5253 | Rhesus macaque | Rhesus macaque TLR3 / CD283 Protein, Fc Tag (MALS verified) |  |
|
|
| TL3-M5255 | Mouse | Mouse TLR3 / CD283 Protein, Fc Tag (MALS verified) |  |
|
|
| TL3-H5253 | Human | Human TLR3 Protein, Fc Tag (MALS verified) |  |
|
The purity of Rhesus macaque TLR3 Protein, Fc Tag (Cat. No. TL3-R5253) is more than 90% and the molecular weight of this protein is around 260-290 kDa verified by SEC-MALS.
The purity of Human TLR3, Fc Tag (Cat. No. TL3-M5255) is more than 90% and the molecular weight of this protein is around 235-287 kDa verified by SEC-MALS.
Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Rintatolimod | Approved | Hemispherx Biopharma Inc | Ampligen, Rintamod | Argentina | Fatigue Syndrome, Chronic | Hemispherx Biopharma Inc | 2017-01-01 | HIV Infections; Ovarian Neoplasms; Pancreatic Neoplasms; Coronavirus Disease 2019 (COVID-19); Mesothelioma; Breast Neoplasms; Influenza, Human; Peritoneal Neoplasms; Colorectal Neoplasms; Fatigue Syndrome, Chronic; Fallopian Tube Neoplasms; Breast Neoplasms, Male; HIV Seropositivity | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| PGV-001 | PGV-001 | Phase 1 Clinical | Genentech Inc, Icahn School Of Medicine At Mount Sinai | Neoplasms | Details |
| TR-987 | Z-101; GLYC-101; MG-3601 | Kazia Therapeutics | Details | ||
| CNTO-5 | CNTO-5 | Phase 1 Clinical | Morphosys Ag | Inflammation | Details |
| Poly ICLC (Oncovir) | Phase 2 Clinical | Yamasa Corp, National Institutes Of Health | Lymphoma, B-Cell; Coronavirus Disease 2019 (COVID-19); Glioblastoma; Pancreatic Neoplasms; Mesothelioma; Breast Neoplasms; Colorectal Neoplasms; Lymphoma, T-Cell; Glioma; Melanoma | Details | |
| Monovalent norovirus Vaccine (Vaxart) | VXA-G1-1-NN; VXA-G1.1-NN | Phase 2 Clinical | Vaxart Inc | Caliciviridae Infections | Details |
| BO-112 | BO-112 | Phase 2 Clinical | Highlight Therapeutics SL | Esophageal Neoplasms; Stomach Neoplasms; Neoplasms; Colorectal Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Melanoma | Details |
This web search service is supported by Google Inc.
A-Z
